Immunome, Inc. (NASDAQ:IMNM) Targets Significant Growth with Public Offering

Leerink Partners sets a price target of $40 for NASDAQ:IMNM, indicating a potential increase of approximately 76.6%.Immunome announces an underwritten public offering aiming to raise$ 400 million to advance cancer therapy developments.The stock price of IMNM has reached a yearly high of $25.30, with today's trading volume hitting 12.54 million shares.Immunome, Inc. (NASDAQ:IMNM) is a biotechnology company focused on developing innovative cancer therapies. On December 15, 2025, Leerink Partners set a price t ...